


Package Leaflet: Information for the User
tamsulosina cinfa 0.4 mg prolonged-release tablets EFG
tamsulosina hydrochloride
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
The active ingredient is tamsulosin. It is a selective antagonist of alpha1A/1D adrenergic receptors. It reduces the tension of the smooth muscles of the prostate and urethra, allowing urine to pass more easily through the urethra and facilitating urination. Additionally, it decreases the sensation of urgency.
tamsulosina cinfa is used in men for the treatment of lower urinary tract symptoms associated with an enlarged prostate gland (benign prostatic hyperplasia). These symptoms include: difficulty urinating (weak urine stream), dripping, urgent urination, and frequent need to urinate both at night and during the day.
Do not take tamsulosina cinfa
Warnings and precautions
Consult your doctor or pharmacist before starting to take tamsulosina cinfa
Children and adolescents
Do not administer this medication to children or adolescents under 18 years of age, as it does not work in this population.
Other medications and tamsulosina cinfa
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication, including those purchased without a prescription.
Taking tamsulosin with other medications in the same group (alpha1 adrenergic receptor blockers) may cause an undesirable drop in blood pressure.
It is especially important that you inform your doctor if you are being treated at the same time with medications that can decrease the elimination of tamsulosin from the body (e.g., ketoconazole, erythromycin).
Taking tamsulosina cinfa with food and drinks
You can take tamsulosin with or without food.
Pregnancy, breastfeeding, and fertility
Tamsulosin is not indicated for use in women.
In men, abnormal ejaculation (altered ejaculation) has been reported. This means that semen is not released through the urethra, but rather into the bladder (retrograde ejaculation) or that the ejaculated volume is reduced or nonexistent (ejaculatory insufficiency). This phenomenon is harmless.
Driving and using machines
There is no evidence that tamsulosin affects the ability to drive or operate tools or machines. However, you should be aware that dizziness can occur, in which case you should not perform activities that require attention.
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. If you have any doubts, consult your doctor or pharmacist again.
The recommended dose is 1 tablet per day. You can take tamsulosin with or without food, preferably at the same time of day.
The tablet should be swallowed whole and not broken or chewed.
Tamsulosin is a tablet designed to release the active ingredient gradually after ingestion. You may observe a residue of the tablet in your stool. There is no risk of loss of efficacy, as the active ingredient has already been released.
Normally, tamsulosin is prescribed for long periods of time. The effects on the bladder and urination are maintained during long-term treatment with tamsulosin.
If you think the effect of tamsulosin is too strong or too weak, inform your doctor or pharmacist.
If you take more tamsulosina cinfa than you should
Taking too many tamsulosin tablets can lead to an undesirable drop in blood pressure and an increase in heart rate, with a feeling of fainting.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take tamsulosina cinfa
If you have forgotten to take tamsulosin as recommended, you can take your daily dose of tamsulosin later that day. If you have missed a dose for a day, you can simply continue taking your daily tablet as prescribed.
Do not take a double dose to make up for forgotten doses.
If you stop taking tamsulosina cinfa
When treatment with tamsulosin is abandoned prematurely, your original symptoms may return. Therefore, take tamsulosin for the entire time your doctor prescribes it, even if your symptoms have disappeared. Always consult your doctor if you decide to stop treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone experiences them.
Common (may affect up to 1 in 10 patients):
Uncommon (may affect up to 1 in 100 patients):
Rare (may affect up to 1 in 1,000 patients):
Very rare (may affect up to 1 in 10,000 patients):
Frequency not known (cannot be estimated from available data):
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in the pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of tamsulosina cinfa
The active ingredient is tamsulosin hydrochloride. Each tablet contains 0.4 mg of tamsulosin hydrochloride.
The other components are:
Appearance of the product and package contents
tamsulosina cinfa tablets are cylindrical, uncoated, white, with the inscription "T9SL" on one side and "0.4" on the other.
They are presented in PVC-PVDC/Aluminum, PVC/Aclar/Aluminum, or PA/Aluminum/PVC-Aluminum blisters.
Each package contains 10, 14, 18, 20, 28, 30, 45, 50, 56, 60, 90, 100, or 200 prolonged-release tablets.
Not all package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
Manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
or
Synthon Hispania S.L.
Castelló 1
Polígono Las Salinas
08830 Sant Boi de Llobregat Spain
or
Synthon BV
Microweg 22
6545 CM Nijmegen Netherlands
Date of the last revision of this package leaflet:November 2020
Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
You can access detailed and updated information about this medication by scanning the QR code included in the package leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/74255/P_74255.html
QR code to: https://cima.aemps.es/cima/dochtml/p/74255/P_74255.html
The average price of TAMSULOSIN CINFA 0.4 mg PROLONGED-RELEASE TABLETS in November, 2025 is around 10.96 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TAMSULOSIN CINFA 0.4 mg PROLONGED-RELEASE TABLETS – subject to medical assessment and local rules.